Anti-tumour necrosis factor (TNF) α treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13
Authors:
- M BombardieriMBM Bombardieri
- F R SpinelliFSF R Spinelli
- R ScrivoRSR Scrivo
- C AlessandriCAC Alessandri
- F ContiFCF Conti
- A SpadaroASA Spadaro
- G ValesiniGVG Valesini
Open Access
- 1 August 2002
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 61 (8) , 723-725
Abstract
Objective: To measure interleukin (IL)18 serum concentrations in patients with rheumatoid arthritis (RA) undergoing infliximab treatment (tumour necrosis factor (TNF) α blockade) and to evaluate the concomitant modification of IL12 and IL13 serum concentrations, two cytokines belonging to the Th1 and Th2 profile respectively and biologically related to IL18. Methods: Ten patients with RA not responding to disease modifying antirheumatic drugs (DMARDs) received intravenous infliximab at a dose of 3 mg/kg at baseline and after two and six weeks. Serum samples were collected from all patients before each infusion and assayed for IL18, IL12, and IL13 by enzyme linked immunosorbent assay (ELISA); IL18 was also measured eight weeks after the last infusion. Results: Serum concentrations of IL18 in all patients were already markedly reduced from baseline after two weeks (pConclusion: There was a rapid and persistent decrease in serum concentrations of IL18 in all the patients studied. This result provides evidence of an in vivo regulation of IL18 by TNFα and suggests that anti-TNFα therapy is likely to interrupt the synergistic effect between these two cytokines.Keywords
This publication has 17 references indexed in Scilit:
- Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's diseaseArthritis & Rheumatism, 2001
- Interferon-?-inducing activity of interleukin-18 in the joint with rheumatoid arthritisArthritis & Rheumatism, 2001
- Interleukin-18 Up-Regulates Osteoprotegerin Expression in Stromal/Osteoblastic CellsBiochemical and Biophysical Research Communications, 2001
- The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defenseImmunology Today, 2000
- The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA)Clinical and Experimental Immunology, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Interleukin-18 Activates the IRAK-TRAF6 Pathway in Mouse EL-4 CellsBiochemical and Biophysical Research Communications, 1998
- Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritisArthritis & Rheumatism, 1998
- Interleukin-18 Activates NF-κB in Murine T Helper Type 1 CellsBiochemical and Biophysical Research Communications, 1997
- The presence of interleukin‐13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritisArthritis & Rheumatism, 1996